Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Carlomagno

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Neuro-Degenerative Diseases|June 29, 2007
Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related proteinGiuseppina Minopoli, Fabiana Passaro, Luigi Aloia, et al.
Cell Reports|January 19, 2016
NCOA4 Deficiency Impairs Systemic Iron HomeostasisRoberto Bellelli, Giorgia Federico, Alessandro Matte', et al.
The Journal of Clinical Endocrinology and Metabolism|March 26, 2013
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancerValentina De Falco, Preziosa Buonocore, Magesh Muthu, et al.
Journal of Medicinal Chemistry|September 7, 2018
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical ApplicationWei Yan, Naga Rajiv Lakkaniga, Francesca Carlomagno, et al.
Cancer Research|December 25, 2002
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinasesFrancesca Carlomagno, Donata Vitagliano, Teresa Guida, et al.
European Journal of Medicinal Chemistry|March 2, 2021
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluationWei Yan, Lingtian Zhang, Fengping Lv, et al.
The Journal of Clinical Endocrinology and Metabolism|May 19, 2005
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinomaTeresa Guida, Giuliana Salvatore, Pinuccia Faviana, et al.
Scientific Reports|May 23, 2025
Ultrasound-induced mechanical damage of cancer cell cytoskeleton causes disruption of nuclear envelope and activation of cGAS-STINGGiorgia Federico, Angelo Rosario Carotenuto, Arsenio Cutolo, et al.
The Journal of Clinical Endocrinology and Metabolism|December 31, 2005
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinomaLeonardo D'Aloiso, Francesca Carlomagno, Michele Bisceglia, et al.
JCO Precision Oncology|August 3, 2023
D898_E901 <i>RET</i> Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent MechanismsTommaso Porcelli, Marialuisa Moccia, Maria Angela De Stefano, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Neuro-Degenerative Diseases|June 29, 2007
Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related proteinGiuseppina Minopoli, Fabiana Passaro, Luigi Aloia, et al.
Cell Reports|January 19, 2016
NCOA4 Deficiency Impairs Systemic Iron HomeostasisRoberto Bellelli, Giorgia Federico, Alessandro Matte', et al.
The Journal of Clinical Endocrinology and Metabolism|March 26, 2013
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancerValentina De Falco, Preziosa Buonocore, Magesh Muthu, et al.
Journal of Medicinal Chemistry|September 7, 2018
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical ApplicationWei Yan, Naga Rajiv Lakkaniga, Francesca Carlomagno, et al.
Cancer Research|December 25, 2002
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinasesFrancesca Carlomagno, Donata Vitagliano, Teresa Guida, et al.
European Journal of Medicinal Chemistry|March 2, 2021
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluationWei Yan, Lingtian Zhang, Fengping Lv, et al.
The Journal of Clinical Endocrinology and Metabolism|May 19, 2005
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinomaTeresa Guida, Giuliana Salvatore, Pinuccia Faviana, et al.
Scientific Reports|May 23, 2025
Ultrasound-induced mechanical damage of cancer cell cytoskeleton causes disruption of nuclear envelope and activation of cGAS-STINGGiorgia Federico, Angelo Rosario Carotenuto, Arsenio Cutolo, et al.
The Journal of Clinical Endocrinology and Metabolism|December 31, 2005
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinomaLeonardo D'Aloiso, Francesca Carlomagno, Michele Bisceglia, et al.
JCO Precision Oncology|August 3, 2023
D898_E901 <i>RET</i> Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent MechanismsTommaso Porcelli, Marialuisa Moccia, Maria Angela De Stefano, et al.
Pageof 7